The Claim

Apigenin does not directly activate SIRT1 in vitro but enhances SIRT1 activity indirectly by increasing NAD+ availability through inhibition of CD38.

Source: Flavonoid Apigenin Is an Inhibitor of the NAD+ase CD38

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
8score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

How it works
1 study reviewed
In plain English

Apigenin does not directly turn on SIRT1 in laboratory cell tests, but it increases the levels of NAD+, which in turn allows SIRT1 to become more active by blocking CD38.

See the scientific wording

Apigenin does not directly activate SIRT1 in vitro, but enhances its activity indirectly by increasing NAD+ availability through CD38 inhibition.

Why this might work

Apigenin blocks a protein that breaks down NAD+, causing NAD+ levels to rise inside cells. The higher NAD+ levels turn on a different protein that removes acetyl groups from other proteins, which changes how cells use energy and reduces fat buildup in the liver.

Verified mechanismbased on 1 study

What the research says

1 study

  1. Study: Flavonoid Apigenin Is an Inhibitor of the NAD+ase CD38

    Apigenin doesn’t turn on SIRT1 directly, but it blocks a protein (CD38) that eats up NAD+, so more NAD+ is available for SIRT1 to use — making SIRT1 work better. The study shows this happens in mice and cells.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.